SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 197 filers reported holding SAREPTA THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 1.31 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $47,518,240 | -2.4% | 392,000 | -7.8% | 1.27% | +9.9% |
Q2 2023 | $48,671,000 | -20.2% | 425,000 | -4.0% | 1.16% | -20.4% |
Q1 2023 | $60,989,775 | +8.0% | 442,500 | +1.5% | 1.46% | +7.1% |
Q4 2022 | $56,496,880 | +18.9% | 436,000 | +1.4% | 1.36% | +10.7% |
Q3 2022 | $47,532,000 | +48.2% | 430,000 | +0.5% | 1.23% | +31.5% |
Q2 2022 | $32,083,000 | -4.0% | 428,000 | 0.0% | 0.93% | +10.9% |
Q1 2022 | $33,435,000 | -12.4% | 428,000 | +0.9% | 0.84% | -4.5% |
Q4 2021 | $38,181,000 | +18.0% | 424,000 | +21.1% | 0.88% | +29.5% |
Q3 2021 | $32,368,000 | +26.7% | 350,000 | +6.5% | 0.68% | +34.9% |
Q2 2021 | $25,557,000 | +4.3% | 328,750 | 0.0% | 0.50% | -5.6% |
Q1 2021 | $24,502,000 | -56.3% | 328,750 | 0.0% | 0.54% | -55.0% |
Q4 2020 | $56,049,000 | +15.5% | 328,750 | -4.8% | 1.19% | -3.5% |
Q3 2020 | $48,519,000 | -12.4% | 345,500 | 0.0% | 1.23% | -19.0% |
Q2 2020 | $55,397,000 | +63.9% | 345,500 | 0.0% | 1.52% | +8.7% |
Q1 2020 | $33,797,000 | -24.2% | 345,500 | 0.0% | 1.40% | -0.9% |
Q4 2019 | $44,583,000 | +75.4% | 345,500 | +2.4% | 1.41% | +39.1% |
Q3 2019 | $25,421,000 | -48.5% | 337,500 | +3.8% | 1.01% | -43.3% |
Q2 2019 | $49,384,000 | +23.9% | 325,000 | -2.8% | 1.79% | +16.3% |
Q1 2019 | $39,869,000 | +11.7% | 334,500 | +2.3% | 1.54% | -8.7% |
Q4 2018 | $35,686,000 | -28.8% | 327,000 | +5.3% | 1.68% | -7.3% |
Q3 2018 | $50,149,000 | +27.5% | 310,500 | +4.4% | 1.82% | +20.0% |
Q2 2018 | $39,324,000 | +105.7% | 297,500 | +15.3% | 1.51% | +85.6% |
Q1 2018 | $19,115,000 | +33.2% | 258,000 | 0.0% | 0.82% | +25.2% |
Q4 2017 | $14,355,000 | +22.1% | 258,000 | -0.5% | 0.65% | +20.1% |
Q3 2017 | $11,757,000 | +70.1% | 259,200 | +26.4% | 0.54% | +55.3% |
Q2 2017 | $6,911,000 | +20.4% | 205,000 | +5.7% | 0.35% | +5.4% |
Q1 2017 | $5,742,000 | +9.1% | 194,000 | +1.1% | 0.33% | -6.0% |
Q4 2016 | $5,264,000 | -50.5% | 191,900 | +10.9% | 0.35% | -47.1% |
Q3 2016 | $10,624,000 | +325.3% | 173,000 | +32.1% | 0.67% | +260.0% |
Q2 2016 | $2,498,000 | -2.3% | 131,000 | 0.0% | 0.18% | -13.6% |
Q1 2016 | $2,557,000 | -58.8% | 131,000 | -18.5% | 0.21% | -54.5% |
Q4 2015 | $6,203,000 | – | 160,800 | – | 0.47% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Perceptive Advisors | 2,878,979 | $69,182,000 | 7.27% |
Eventide Asset Management | 259,100 | $6,226,000 | 0.97% |
GLADE BROOK CAPITAL PARTNERS LLC | 251,000 | $6,032,000 | 0.93% |
IMS Capital Management | 32,215 | $774,000 | 0.91% |
Perceptive Advisors | 350,000 | $8,413,000 | 0.88% |
Benchmark Capital Advisors | 34,900 | $839,000 | 0.58% |
BECK CAPITAL MANAGEMENT, LLC | 24,744 | $636,000 | 0.49% |
SABBY MANAGEMENT, LLC | 352,100 | $8,461,000 | 0.47% |
Hatteras Alternative Mutual Funds, LLC | 39,404 | $947,000 | 0.46% |
Potomac Capital Management, Inc. | 22,100 | $531,000 | 0.45% |